Intangible Assets

CGTX appears to have limited evidence of proprietary assets or protected IP that translate into durable pricing power versus peers, so any advantage is likely weak and non-exclusive.

As a clinical-stage biotech, value depends on pipeline assets rather than established commercial intangibles, which makes peer differentiation contingent on trial outcomes rather than entrenched market position.

No filing-based evidence provided here indicates a broad patent estate, regulatory exclusivity, or brand strength that would materially sustain margins or retention over 5–10 years versus better-capitalized peers.

Compared with commercial-stage peers that already monetize approved products, CGTX lacks demonstrated intangible assets that customers or partners are structurally dependent on.

Switching Costs

CGTX does not appear to operate a commercial platform with installed-base workflows, so customers are unlikely to face meaningful switching costs versus peers.

Without approved products, recurring usage, or integrated clinical infrastructure, retention is driven by development progress rather than customer lock-in.

Peer companies with approved therapies or embedded service relationships typically enjoy higher switching friction, while CGTX currently shows no comparable evidence of lock-in.

The provided metrics do not indicate revenue durability or operating scale that would create practical switching barriers over a 5–10 year horizon.

Network Effects

CGTX shows no evidence of network effects because its business model does not rely on a user ecosystem, marketplace, or data network that compounds with scale.

Clinical-stage development can benefit from scientific attention, but that is not a durable network effect that materially improves pricing power versus peers.

Unlike platform or data-rich peers, CGTX does not appear to have a self-reinforcing adoption loop that would make customers or partners increasingly dependent on it.

No provided filing or market evidence suggests ecosystem control or peer dependency that would support a network-effect moat.

Cost Advantage

The negative ROIC and ROCE in the provided metrics indicate that CGTX is not currently converting capital into returns more efficiently than peers, which argues against a cost advantage.

A clinical-stage company typically lacks the manufacturing scale, procurement leverage, or process maturity needed to sustain lower unit costs than established competitors.

The extremely negative cash conversion cycle is not evidence of structural cost advantage here because it likely reflects working-capital dynamics rather than durable operating efficiency.

Compared with larger biopharma peers, CGTX does not show a visible cost base advantage that would protect margins or pricing power over time.

Efficient Scale

CGTX does not appear to operate in a market structure where a small number of firms can profitably serve the entire market, so efficient-scale protection is limited.

The company is not shown to control scarce infrastructure, regulated capacity, or a bottleneck asset that would deter peer entry.

Compared with incumbents that own approved products, manufacturing networks, or distribution reach, CGTX lacks evidence of scale-based barriers that would preserve share.

The available metrics do not support the presence of a stable, high-return niche where additional competitors would be uneconomic.

Overall Score

CGTX shows no clear evidence of a durable economic moat versus peers because it lacks demonstrated switching costs, network effects, cost advantage, or efficient-scale protection, and the provided profitability metrics are negative rather than moat-confirming.